Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Open Access
- 31 July 2021
- journal article
- research article
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 54 (7) , 386-391
Abstract
Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim & Myung-Ju Ahn. BMB Reports 2021;54:386-91. https://doi.org/10.5483/BMBRep.2021.54.7.045Keywords
Funding Information
- Bristol Myers Squibb
This publication has 35 references indexed in Scilit:
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and ChallengesCancers, 2015
- Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancerOncotarget, 2015
- Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing ApproachesClinical Cancer Research, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomesFrontiers in Genetics, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Signatures of mutational processes in human cancerNature, 2013